Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer
Oncologist - United States
doi 10.1634/theoncologist.2019-0299
Full Text
Open PDFAbstract
Available in full text
Date
November 19, 2019
Authors
Publisher
Alphamed Press